For two decades, leukaemia stem cells (LSCs) in chronic myeloid leukaemia (CML) and
acute myeloid leukaemia (AML) have been advanced paradigms for the cancer stem cell …

Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European …

Recent advances in single-cell transcriptomics are ideally placed to unravel intratumoral
heterogeneity and selective resistance of cancer stem cell (SC) subpopulations to …

The differentiation of tumorigenic cancer stem cells into nontumorigenic cancer cells confers
heterogeneity to some cancers beyond that explained by clonal evolution or environmental …

The cancer stem cell (CSC) concept derives from the fact that cancers are dysregulated
tissue clones whose continued propagation is vested in a biologically distinct subset of cells …

Chronic myeloid leukemia (CML) is caused by the acquisition of the tyrosine kinase BCR-
ABL1 in a hemopoietic stem cell, transforming it into a leukemic stem cell (LSC) that self …

The truncated chromosome 22 that results from the reciprocal translocation t (9; 22)(q34;
q11) is known as the Philadelphia chromosome (Ph) and is a hallmark of chronic myeloid …

The advent of tyrosine kinase inhibitors (TKI) into the management of patients with chronic
myeloid leukemia (CML) has profoundly improved prognosis. Survival of responders is …

Recent evidence suggests chronic myeloid leukemia (CML) stem cells are insensitive to
kinase inhibitors and responsible for minimal residual disease in treated patients. We …

Chronic myeloid leukemia (CML) originates in a hematopoietic stem cell (HSC) transformed
by the breakpoint cluster region (BCR)-abelson (ABL) oncogene and is effectively treated …